CHENG-HSUAN TSAICHI-CHAO CHAOSUNG-TSANG HSIEHYu, An-LiAn-LiYuWu, Yuan-Kun AdenYuan-Kun AdenWuMEI-FANG CHENGMING-JEN LEEChou, Chia-HungChia-HungChouCHIA-TUNG SHUNHSUEH-WEN HSUEHJYH-MING JIMMY JUANGPING-HUEI TSENGMAO-YUAN SUYEN-HUNG LIN2023-10-202023-10-202023-121750-1172https://pubmed.ncbi.nlm.nih.gov/37705003/https://scholars.lib.ntu.edu.tw/handle/123456789/636409Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are unknown. This study aimed to used cardiac magnetic resonance (CMR) to investigate the effects of tafamidis on patients with hereditary A97S ATTR-CM.enCardiac magnetic resonance; Extracellular volume; Hereditary transthyretin amyloidosis; Tafamidis[SDGs]SDG3Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort studyjournal article10.1186/s13023-023-02824-0377050032-s2.0-85171138165